Press Releases
Updated Phase III PIVOTAL Results for Nidlegy™ Published in the Journal of Clinical Oncology
Longer-term analysis confirms the clinical benefit of neoadjuvant Nidlegy™ in locally advanced, fully resectable melanoma The publication represents an update of the PIVOTAL Phase III results previously published in Annals...
Read moreNidlegy™ Marketing Authorization Application Resubmitted to EMA
Siena, Italy, 27 July 2026 – Philogen S.p.A. (BIT:PHIL) is pleased to announce the submission of an updated Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the...
Read moreUpcoming Events
Philogen is pleased to invite you to an upcoming webinar on September 25, 2026, at 14:00 GMT | 15:00 CET.
During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link or contact us at IR@philogen.com for...
Read morePhilogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026
Dr. Ettore Gilardoni will present a poster entitled “Mass Spectrometry–Based Atlas of the Blood-Accessible Surface Proteome in Syngeneic Brain Tumor Models”.
Follow the link for more information
Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026
Prof. Philipp Backhaus will give a presentation on “Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [68Ga]Ga-OncoACP3-DOTA PET and first experience with [177Lu]Lu-OncoACP3-DOTA in Prostate Cancer Patients”. Follow the link for more details....
Read morePast Events
Philogen to attend the Festival of Biologics, 13-15 October 2026
Dr. Ettore Gilardoni will give an oral presentation entitled “Charge Variants characterization of a noncovalent dimeric fusion protein”.
Follow the link for more details
Philogen to attend AACR 2026 in San Diego, 17-22 April 2026
Dr. Matilde Bocci is presenting a poster entitled “FAP-targeting Small molecule-immunostimulator conjugate bearing a novel TLR7 agonist payload induces tumor eradication and long-lasting antitumor immunity in vivo”. Dr. Abdullah Elsayed...
Read morePhilogen to attend EADO 2026, 23-25 April 2026
Prof. Thomas Eigentler will give a talk entitled “Intralesional L19IL2/L19TNF in high-risk lacSCC patients: results from the Phase II DUNCAN Trial Exploratory Cohort”.
Follow the link for more details.